论文部分内容阅读
Objective: To observe the heart function、MEE and serum FFA of Shenqiyixin prescription for heart qi (yang) deficiency with blood stasis and fluid retention type of chronic heart failure patients, to evaluate the clinical efficacy and safety. Methods: 64 cases with chronic heart failure of heart qi (yang) deficiency with blood stasis and fluid retention were randomly divided into two groups, 3 cases were excluded, 31 cases in the control group and 30 cases in the treatment group. The control group was treated with western medicine, and the treatment group was treated with Shenqiyixin prescription additionally. The course of treatment was 3 weeks. Observe the changes of TCM syndrome score, 6MWD, LVEF, cESS, MEE, serum NT-proBNP, serum FFA and safety indexes of each group before and after treatment. Results: after treatment, the TCM Syndromes of each group were improved. The total effective rate of the treatment group was 93.33％, and the control group was 83.87％. The treatment group was more effective (P<0.05). After treatment, the TCM syndrome score, cESS, MEE, NT-proBNP and FFA of each group were decreased, 6MWD and LVEF were increased (P<0.05), and the treatment group was superior to the control group (P<0.05). Conclusion: Shenqiyixin prescription can improve the TCM syndrome and heart function in patients with chronic heart failure of heart qi (yang) deficiency with blood stasis and fluid retention, at the same time, it can reduce the level of MEE and serum FFA in patients with heart failure.